According to Acumen Research and Consulting, the Glycomics/Glycobiology Market value is poised to reach around US$ 2.2 billion by 2026 growing at noteworthy CAGR around 14.3 % throughout the forecast period 2019 to 2026.
The report provides analysis of global Glycomics/Glycobiology market for the period 2015-2026, wherein 2019 to 2026 is the forecast period and 2018 is considered as the base year.
The market should be driven by technological advances. Another significant contributing factor is the increased investment of different public institutions in studies and the creation of new drugs by pharmaceutical and biotechnology firms. Moreover, an increasing focus on research into glycomics and proteomics is expected to promote market growth in the near future. Increasing government and organizational investments have allowed academic scientists to create new instruments for glycomics and glycobiology. This factor is expected to drive the glycoscience field and thus the market as a whole. Advanced analytical methods for pathogen and human glycobiology in disease and health are required in glycoproteomics.
Biomedical research and proteomics have thus increased and this industry is growing. Increasing demand for glycomic tools also led to technological developments. Approaches like protein characterization are developing into state-of - the-art technology, such as HPC, Mass Spectrometry (MS) and Capillary Electrophoresis (CE) in studies involving chemicals and biochemistry. These state-of - the-art methods deliver quick and responsive outcomes. Pharmaceutical and biotechnology firms are increasingly engaged in R&D, including studies into glycomics. Thermo Fisher Scientific, for example, in 2017 invested about USD 888 million in research and development. Dollar 339 million for R&D invested by Agilent Technologies in 2017. Small pharmaceutical companies also spend more on research and development. In future years, this factor is expected to accelerate market growth.
Due to frequent use in drug discovery and diagnostic testing the tools held the biggest market share in 2018. In addition, repeated buying of reagents and kits will also increase the development of the segment. The increase in studies in cancer therapy and diagnosis is projected to account for a large part of the market in the near future.
Glycomics utilizes different study methods to quantify or describe tissue, cell or organism glycoma. Alteration of enzymes engaged in glycan biosyntheses such as location or activity eventually leads to the change of the final glycan structure. Therefore, glycans can be evaluated in order to evaluate environmental changes in addition to genetic markups of people. In disease diagnosis and drug discovery this research can be used. This is one of the main variables driving development in the segment. Many studies were performed on the marketing of glycoside inhibitors known to change n-linked cancer cell and virus glycans. Direct antiviral, antibacterial and anti-cancer operations are included in the treatment of these enzymes. They help treat deficiency diseases like Tay-Sachs and Gaucher, and, more importantly, diabetes. they help to treat the illnesses. Thus, glycosidases were the most important market share among enzymes in terms of income. From 2019 to 2026, the section is expected to see CAGR 16.2%. Different study studies show the development of new glycan structures by epigenetic glycannic regulation in cancer cells. These buildings are one way of avoiding immune response in a hosts by cancerous cells. Genetically engineered cell models are intended by scientists to know the function of certain epitopes of glycancer. These factors are expected in the forecast period to boost market growth.
End Use Stance
Academic and scientific institutes accounted for the biggest share of income in 2018 because of enhanced investment in R&D. The segment expansion is further supported by cooperation between significant organisations and study institutes. Due to increased investment in R & D in drug research, research and growth, and further glycobiology research, the Pharma and biotechnology segment is expected to record the highest CAGR during the preliminary period.
The increasing acceptance by study centers of the evaluation of glycan structure information also adds to the development of the segment. Another factor contributing to the segment development is glycomic preference for education and training. The market is anticipated to be driven in the near future by a broad variety of apps in drug discovery and growth, biomedical research, cell biology, immunology and biochemistry.
The discovery and growth of drugs represented the biggest market share in 2018, on the grounds of their implementation. This is mainly due to comprehensive R&D and enhanced public financing for glycomics and proteomics studies. During the forecasting period, the other application segment is expected to be the largest CAGR owing to increased research and research costs incurred by important research firms. In 2018, for example, Merck's R&D spending was $2.3 billion. The extensive applications of the glycanstructured study in bioinformatics increase glycene research, which contributes to the identification and evaluation of drug targets and biomarkers. Glycomics includes the study of biological system features and constructions of glycans. It is thus appropriate for early identification of illnesses in personalized drugs to select the appropriate therapy line.
The existence of important pharmaceutical and biopharmaceutical firms accounted for North America's biggest share of the market in 2018. The regional market has been motivated by the presence of well established healthcare facilities and access to developed goods. In addition, public financing for R&D is another major factor in boosting the market development of glycobiology in this area.
Due to untapped market possibilities, Asia Pacific is anticipated to become the second fastest growing national market in the forecast. Developing pharmaceutical and biopharmaceutical sectors have led to huge glycomic development in the area. Furthermore, the growth of the Asia-Pacific glycomes / glycobiology industry should be stimulated by investments by the Contract research organizations (CROs) in the development and manufacturing of drugs and biologics.
Bio-based industries in Europe are projected to provide worldwide competitive advantages for glycoscience with their importance in contemporary biotechnology and their capacity to access fresh and innovative technologies. The existence of major Pharmaceutical companies and changing healthcare infrastructure is anticipates that Latin America will see steady growth due to quickly developing economies. During the forecast period, Brazil is anticipated to grow in a profitable CAGR due to the increase of studies related to life science and health infrastructures development.
Global Glycomics/Glycobiology Market, By Product
Global Glycomics/Glycobiology Market, By Application
Global Glycomics/Glycobiology Market, By End Use
Global Glycomics/Glycobiology Market, By Geography
The market research study on “Glycomics/Glycobiology Market - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026” offers detailed insights on global Glycomics/Glycobiology market segments with market dynamics and their impact. The report also covers basic technology development policies.
Key Players & Strategies
Agilent Technologies, Thermo Fisher Scientific, Inc., Takara Bio, Inc., Merck KGaA, Bruker, Shimadzu Corporation, Biolabs, Danaher, and ProZyme are among the main businesses on the market. Most of these businesses have a wide product range and powerful regional presence.
The main strategies conducted by these businesses for sustainable growth are new product launches, mergers and acquisitions, alliances and collaborations. Merck KGaA spent, for example, EUR 40 million in February 2018 to improve its facilities in the Asian region for distribution and manufacture.
In another case, Agilent Technologies acquired ULTRA Scientific Assets, which distributes accredited chemical products and norms, in July 2018. The objective of this purchase was to offer the business alternatives for life-science and to establish a broader consumer base.
Glycomics is a comparatively new technology and its innovative applications are being researched. Major market participants in glycomics therefore collaborate in the growth of newer technology with the educational institutions. In cooperation with the University of Southern California, for example, Agilent Technologies has facilitated scientists in the diagnostic sector, in fresh drug growth and in medical devices.
The market should be driven by technological advances. Another significant contributing factor is the increased investment of different public institutions in studies and the creation of new drugs by pharmaceutical and biotechnology firms.
According to Acumen Research and Consulting, the glycomics/glycobiology market value is anticipated to be worth around US$ 2.2 billion in 2026.
The glycomics/glycobiology market is anticipated to grow over 14.3% CAGR during the forecast period 2019 to 2026.
Due to frequent use in drug discovery and diagnostic testing the tools held the biggest market share in 2018.
Academic and scientific institutes accounted for the biggest share of income in 2018 because of enhanced investment in R&D.
The existence of important pharmaceutical and biopharmaceutical firms accounted for North America's biggest share of the market in 2018.
Agilent Technologies, Thermo Fisher Scientific, Inc., Takara Bio, Inc., Merck KGaA, Bruker, Shimadzu Corporation, Biolabs, Danaher, and ProZyme are among the main businesses on the market.